X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs PANACEA BIOTECH - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD PANACEA BIOTECH MERCK LTD/
PANACEA BIOTECH
 
P/E (TTM) x 44.0 -6.3 - View Chart
P/BV x 6.4 1.9 342.9% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 MERCK LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    MERCK LTD
Dec-17
PANACEA BIOTECH
Mar-14
MERCK LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,358149 912.9%   
Low Rs93382 1,133.7%   
Sales per share (Unadj.) Rs665.084.1 790.4%  
Earnings per share (Unadj.) Rs56.6-18.3 -309.0%  
Cash flow per share (Unadj.) Rs72.5-6.7 -1,081.9%  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs441.783.7 527.7%  
Shares outstanding (eoy) m16.6061.25 27.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.71.4 125.5%   
Avg P/E ratio x20.2-6.3 -320.9%  
P/CF ratio (eoy) x15.8-17.2 -91.6%  
Price / Book Value ratio x2.61.4 187.9%  
Dividend payout %26.50-   
Avg Mkt Cap Rs m19,0117,074 268.7%   
No. of employees `0001.52.8 56.1%   
Total wages/salary Rs m1,6961,449 117.1%   
Avg. sales/employee Rs Th7,150.01,874.1 381.5%   
Avg. wages/employee Rs Th1,098.7527.0 208.5%   
Avg. net profit/employee Rs Th608.2-407.7 -149.2%   
INCOME DATA
Net Sales Rs m11,0405,154 214.2%  
Other income Rs m240100 240.2%   
Total revenues Rs m11,2795,254 214.7%   
Gross profit Rs m1,376-766 -179.6%  
Depreciation Rs m264711 37.1%   
Interest Rs m01,503 0.0%   
Profit before tax Rs m1,352-2,881 -46.9%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m1701,771 9.6%   
Tax Rs m58317 3,469.0%   
Profit after tax Rs m939-1,121 -83.8%  
Gross profit margin %12.5-14.9 -83.8%  
Effective tax rate %43.1-0.6 -7,391.5%   
Net profit margin %8.5-21.8 -39.1%  
BALANCE SHEET DATA
Current assets Rs m7,5233,810 197.5%   
Current liabilities Rs m2,2538,365 26.9%   
Net working cap to sales %47.7-88.4 -54.0%  
Current ratio x3.30.5 733.3%  
Inventory Days Days52156 33.5%  
Debtors Days Days4167 60.3%  
Net fixed assets Rs m1,24014,480 8.6%   
Share capital Rs m16661 270.8%   
"Free" reserves Rs m7,167903 793.6%   
Net worth Rs m7,3335,127 143.0%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m9,91219,433 51.0%  
Interest coverage xNM-0.9-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.10.3 420.0%   
Return on assets %9.52.0 482.4%  
Return on equity %12.8-21.9 -58.6%  
Return on capital %20.83.6 570.8%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m1,0151,539 65.9%   
Fx outflow Rs m3,043942 323.0%   
Net fx Rs m-2,028597 -339.6%   
CASH FLOW
From Operations Rs m537599 89.6%  
From Investments Rs m-476-438 108.8%  
From Financial Activity Rs m-220-303 72.6%  
Net Cashflow Rs m-160-141 112.9%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.6 3,033.3%  
FIIs % 1.0 1.3 76.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 23.6 123.3%  
Shareholders   28,591 10,259 278.7%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare MERCK LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Dec 12, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD 8-QTR ANALYSIS

COMPARE MERCK LTD WITH

MARKET STATS